Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Heat-perception Protein Finding May Lead to New Pain Therapies

A ribbon diagram depicting the structure of the TRPV2 ion channel (blue, yellow, green) as it lies embedded in the cell membrane (orange and white). This ion channel is a temperature sensor involved in the perception of pain and heat, and therapies targeting i

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A ribbon diagram depicting the structure of the TRPV2 ion channel (blue, yellow, green) as it lies embedded in the cell membrane (orange and white). This ion channel is a temperature sensor involved in the perception of pain and heat, and therapies targeting it could one day alleviate suffering in people afflicted with chronic pain. [Mark A. Herzik Jr., Scripps Research Institute]

Scientists at the Duke University School of Medicine have discovered the structure of a protein linked to pain and heat perception. An ion channel in the cell surface membrane, TRPV2 plays a role in a number of biological processes, such as maintaining a healthy heart, helping dispose of pathogens, and inducing cell death in certain cancers.

The researchers believe their study (“Cryo-electron microscopy structure of the TRPV2 ion channel”), published in Nature Structural Biology and Molecular Biology, is an important step toward new therapies that target pain receptors. More than 100 million Americans suffer from some sort of severe or chronic pain, a condition that is underdiagnosed and poorly treated.

“These receptors are gaining particular attention because they are so critical to how we sense and respond to our environment,” said senior study author Seok-Yong Lee, Ph.D., assistant professor of biochemistry at Duke University School of Medicine. “Our results give a hint as to how one receptor works, a necessary component for developing new treatments for a variety of conditions involving sensation.”

Ion channels are scattered across all cell membranes and act as gatekeepers of information flowing in and out of cells. In the case of TRPV (Transient Receptor Potential Vanilloid, pronounced trip-vee), this information takes the form of calcium ions. Like the turning of a valve, TRPV receptors open in response to noxious heat or other stimuli, allowing an influx of calcium ions that convey a signal through the nervous system to the brain.

But how do such valves open and close? Structural biologists like Dr. Lee believe that deducing the schematics of these valves can give them the blueprint for designing drugs that target ion channels. Recently, researchers solved the structure of the first protein in the TRPV superfamily, TRPV1. Their results gave a picture of the protein in two different states—when it was open to the flow of ions and when it was closed off.

In this study, Dr. Lee wanted to determine the structure of the next in line, TRPV2. Unlike TRPV1, which is only found in the nervous system, TRPV2 is present throughout the body and has been implicated in a variety of human conditions, including heart disease, the immune response, and cancer. But taking a picture of this protein was harder than it sounds. It took Dr. Lee several years to work out the right conditions to keep the protein well dispersed and stable in biochemical solution, so it could be flash frozen and visualized by a technique known as cryo-electron microscopy.

Gabriel Lander, Ph.D., a biologist at the Scripps Research Institute in La Jolla, CA, used this advanced technique to determine the structure of TRPV2 at near-atomic resolution. Cryo-electron microscopy works much like regular electron microscopy: electrons are shot at the sample, refracting or bouncing back from dense areas and passing through empty ones. In all, Dr. Lander took about half a million 2D images, which he then ran through a sophisticated computer program to generate a 3D picture of the protein.

When the researchers compared the structure of TRPV2 to TRPV1, they were surprised to find that it didn't fit the mold for either the open or closed confirmation of the closely related protein. Rather, it seemed to inhabit an in-between stage, suggesting a third state where the channel becomes desensitized to repeated stimuli, much like a person might get used to the beeps of a faulty smoke detector. Dr. Lee thinks that studying this desensitized state could point to a way to alleviate chronic pain in people.

Currently, Dr. Lee is trying to create biochemical conditions that will coax TRPV2 into other conformations so that he and his colleagues can determine its structure when it is open or closed. He also plans to find the structures of other proteins in the TRPV superfamily.

“If we can obtain these different conformations, we can generate a series of snapshots, perhaps even an entire movie, that will allow us to understand how this machine operates,” said Dr. Lee.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →